New hope for advanced liver cancer: SH006 combo trial launches
Disease control
Not yet recruiting
This study tests a new drug combination (SH006 injection) against a standard treatment (regorafenib) for people with advanced liver cancer that has not responded to previous immunotherapy. About 120 adults aged 18-75 will participate. The goal is to see if the new combo can slow …
Phase: PHASE2, PHASE3 • Sponsor: Nanjing Sanhome Pharmaceutical, Co., Ltd. • Aim: Disease control
Last updated May 12, 2026 13:43 UTC